Updated on 9 September 2026
Medix ProClot
Regional Director at Medix ProClot
Taiwan
About
Medix ProClot is an agile medical innovator developing next-generation hemostatic (blood-clotting) solutions designed for both human and veterinary applications. By eliminating traditional prescription barriers and addressing regional supply chain inefficiencies, we deliver immediate, high-efficacy wound care across Asia-Pacific and emerging global markets.
Core Innovation & Competitive Edge
Superior Efficacy: Field-tested performance surpassing incumbent trauma gels (e.g., QuikClot, Celox), achieving rapid hemostasis for critical and everyday wound care.
Unlocking the Prescription Gap: Traditional hemostatic agents in APAC often require doctors' prescriptions, creating costly delays for basic bleeding management. We offer direct-access, highly effective solutions that lower barriers for end-users.
Optimized Unit Economics & LTV: Redesigned from cumbersome 30ml bulk units to compact 10ml and 20ml portable formats. This right-sizing accelerates consumption velocity and maximizes Customer Lifetime Value (LTV).
Taiwan Manufacturing Excellence: Partnered with leading Taiwanese CMOs holding extensive US FDA and TFDA clearance track records, ensuring top-tier regulatory compliance and manufacturing quality.
Market Traction & Growth Momentum
Rapid APAC Rollout: Secured MOUs across 4 APAC countries within our first year of operation.
Proven Market Pull: Sustaining strong organic demand without discounting. Recent trade showcases generated 160+ consumer waitlists, along with direct procurement inquiries from national defense units.
Disrupting Legacy Distribution: Traditional distributors of legacy brands face rigid bureaucracy, stock dumping, and a lack of local customer support. We offer direct, agile collaboration backed by genuine localized service—attracting top-tier regional distributors to our network.
Impact-Driven Business Model
Direct-to-Distributor Structure: Eliminates unnecessary middle layers to protect profit margins for all channel partners.
ESG & Social Impact Marketing: Brand awareness driven by direct support to stray animal shelters, capturing high consumer willingness-to-pay through social value.
Subscription & Event Packages: Expanding B2B channels through athletic event emergency kits (e.g., cycling event packages) and recurring membership models.
Project Location
- United States
Project Website
https://medixproclot.com/videos-2/
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Technology
Technology
- Bio-Tech
- Health Technology
- Medical Technology
Urban Development
- Health Facilities
Total Project Value
- 7,500,001 to 10,000,000 USD
Investment Capital Required
- 2,500,001 to 5,000,000 USD
Interested Format of Cooperation
- Open for Negotiation
Preferred Financing Model
- Equity
- Open for negotiation
Type(s) of Last Financing Round of the project (if Applicable)
- Equity (private)
Main Service(s) Required
- Financial Services
- Professional Services
Financial Services
- Commercial Banking
- Investment Banking
- Mergers & Acquisition
- Private Banking
- Private Equity & Venture Capital
Information Technology Services
- E-commerce
Organisation
United States
Similar opportunities
Project
- Yes
- Yes
- Equity
- Fin-Tech
- Bio-Tech
- Technology
- Agro-Industry
- Joint Venture
- Bootstrapping
- Seeking for Tenant
- Financial Services
- ICT And Data Center
- Open for negotiation
- Open for Negotiation
- Other Renewable Energy
- 500,001 to 1,000,000 USD
- 1,000,001 to 2,500,000 USD
- Investment / Financing Discussion
- Public-Private Partnership Project
- Agriculture, Food and Rural Development
- Public–private partnership / Concession
- M&A / Strategic Acquisition Opportunity
Fatih Yucel
General Coordinator at Socin Lab
Türkiye
Project
- Yes
- Yes
- Technology
- Private Project
- Islamic Finance
- Equity (private)
- Medical Technology
- Financial Services
- Open for negotiation
- Open for Negotiation
- Institutional Investment
- 2,500,001 to 5,000,000 USD
- Feasibility Study Completed
- Private Equity & Venture Capital
Dabriel Choi
CEO at EveryBaby
China (Hong Kong)
Project
Europe expansion in mobile accesories sector
- Yes
- Yes
- Equity
- Manufacturing
- Joint Venture
- Private Project
- Convertible Loan
- Equity (private)
- Financial Services
- Investment Banking
- Open for negotiation
- Open for Negotiation
- Mergers & Acquisition
- Majority Shareholdings
- Minority Shareholdings
- Direct Equity Investment
- 25,000,001 to 50,000,000 USD
- Private Equity & Venture Capital
- Investment / Financing Discussion
- M&A / Strategic Acquisition Opportunity
Vlad Pasca
Business Partner at CONTAKT
Romania